StreetAlpha.app
Home › Stocks › HIND

Vyome Holdings, Inc (HIND)

$1.51
▲ +0.67%
LAST CLOSE · NOV 17

Vyome develops treatments for rare and immune inflammatory diseases and sells antifungal products in India. It last closed at $1.51 on Nov 17, up 0.67% on the day.

AI Auto Pilots
Is HIND in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$153K
−55.6% vs a year ago
Net income
−$3.8M
−2455.6% margin
Gross margin
50.4%
$77K gross profit
Operating margin
−2853.6%
−$4.4M operating income
Valuation
Market cap
$10.6M
7.0M shares
P/E
–
Price to sales
69.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$7.0M
At Sep 30
Shares outstanding
7.0M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $13.6M$13.6MFY2021FY2022: $11.2M$11.2MFY2022FY2023: $8.7M$8.7MFY2023FY2024: $257K$257KFY2024FY2025: $320K$320KFY2025

From HIND's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated HIND in the past 90 days, not enough for a consensus
Average 12-month target
$3.50
▲ 131.8% upside

Based on 1 analyst who set a price target on HIND in the past 90 days. The average target is $3.50, with a high of $3.50 and a low of $3.50, compared with the last close of $1.51.

Low $3.50Avg $3.50High $3.50
Blue marker: last close $1.51
Highest target$3.50
Average target$3.50
Lowest target$3.50
Latest rating changes
Chardan CapitalInitiated
Sep 3Buy$3.50
DateFirmActionRatingPrice target
Sep 3Chardan CapitalInitiatedBuy$3.50
Loading…

Technical Analysis

HIND · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 11% below its 20 day and 23% below its 50 day average. It is 44% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the 52 week low at $1.49, and the nearest resistance the Pivot at $1.52.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 6.5%/day
Key levels
$5.8852 week high+289.4%
$2.18200 day average+44.4%
$2.02100 day average+33.8%
$1.8650 day average+23.2%
$1.72Swing high (Nov 11)+13.9%
$1.6820 day average+11.3%
$1.54Pivot R1+2.0%
$1.52Pivot+0.7%
$1.51Last close
$1.4952 week low−1.3%
$1.48Pivot S1−2.0%
Indicators
RSI (14)29.75Oversold below 30Oversold
MACD-0.10Below its signal lineBearish
Stochastic4.3Near the bottom of its rangeOversold
ADX (14)13.7No clear trend
Williams %R-96.9Oversold below −80, overbought above −20Oversold
CCI (20)-117.6Oversold below −100, overbought above 100Oversold
Rate of change−14.7%Change over 10 sessionsBearish
ATR (14)$0.10Typical daily range, 6.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for HIND

What happened before

See how HIND did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in HIND in the last 90 days.

Loading…

See today’s whale options flow across the market →

HIND Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼4 buying vs 6 selling
  • ●Held by funds -0.3 pts
  • ●Funds holding +0
  • ▼Superinvestors: 0 added, 1 cut
  • ●Put/call not meaningful
Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding12120.0%
In funds' top 1000–
Held by funds1.7%2.0%−0.3 pts
New / increased1 / 34 / 3−42.9%
Reduced / sold out5 / 11 / 1+200.0%
Put/call ratio–––
SuperinvestorsKen GriffinSold out
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See HIND institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HIND is in one of them and how their past HIND trades turned out.

HIND in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered HIND in an article yet. Here's the latest on the wider market.

About Vyome Holdings

Vyome is a clinical stage specialty pharmaceutical company developing treatments for immune inflammatory and rare diseases. Its lead program is a topical gel for symptoms of malignant fungating wounds in advanced cancer. Its other development programs target uveitis, an eye condition, and moderate to severe acne, and none of its candidates is approved for sale. The company also sells dandruff lotion and shampoo, both antifungal products, in India through a licensing partner, Sun Pharma. It is based in San Clemente, California, with operations in Massachusetts, New Jersey and New Delhi, India.

Headquarters
San Clemente, CA